

# Virginia Piñol

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8937976/publications.pdf>

Version: 2024-02-01

40  
papers

2,709  
citations

257450

24  
h-index

289244

40  
g-index

41  
all docs

41  
docs citations

41  
times ranked

3368  
citing authors

#	ARTICLE	IF	CITATIONS
1	Accuracy of Revised Bethesda Guidelines, Microsatellite Instability, and Immunohistochemistry for the Identification of Patients With Hereditary Nonpolyposis Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1986.	7.4	457
2	Postoperative Surveillance in Patients With Colorectal Cancer Who Have Undergone Curative Resection: A Prospective, Multicenter, Randomized, Controlled Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 386-393.	1.6	259
3	POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. <i>Genetics in Medicine</i> , 2016, 18, 325-332.	2.4	209
4	Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. <i>Gut</i> , 2006, 55, 848-855.	12.1	199
5	Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. <i>Gut</i> , 2012, 61, 865-872.	12.1	172
6	Performance of Different Microsatellite Marker Panels for Detection of Mismatch Repair-Deficient Colorectal Tumors. <i>Journal of the National Cancer Institute</i> , 2007, 99, 244-252.	6.3	157
7	Percutaneous Self-expanding Metal Stents versus Endoscopic Polyethylene Endoprostheses for Treating Malignant Biliary Obstruction: Randomized Clinical Trial. <i>Radiology</i> , 2002, 225, 27-34.	7.3	147
8	Differential Features of Colorectal Cancers Fulfilling Amsterdam Criteria without Involvement of the Mutator Pathway. <i>Clinical Cancer Research</i> , 2005, 11, 7304-7310.	7.0	119
9	Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. <i>Gut</i> , 2016, 65, 1829-1837.	12.1	93
10	Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer. <i>Gut</i> , 2007, 56, 1714-1718.	12.1	85
11	Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 39-45.	1.6	72
12	Lack of prognostic influence of circulating tumor cells in peripheral blood of patients with colorectal cancer. <i>Gastroenterology</i> , 2001, 120, 1084-1092.	1.3	70
13	Detection of Metachronous Neoplasms in Colorectal Cancer Patients: Identification of Risk Factors. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 971-980.	1.3	64
14	The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. <i>International Journal of Cancer</i> , 2017, 140, 2201-2211.	5.1	61
15	Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients. <i>BMC Medicine</i> , 2016, 14, 128.	5.5	56
16	Synchronous Colorectal Neoplasms in Patients With Colorectal Cancer: Predisposing Individual and Familial Factors. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 1192-1200.	1.3	55
17	Evidence suggests that germline <i>RNF43</i> mutations are a rare cause of serrated polyposis. <i>Gut</i> , 2018, 67, 2230-2232.	12.1	48
18	Prognostic Value of Postoperative Detection of Blood Circulating Tumor Cells in Patients With Colorectal Cancer Operated on For Cure. <i>Annals of Surgery</i> , 2003, 237, 368-375.	4.2	41

#	ARTICLE	IF	CITATIONS
19	Clinical Performance of Original and Revised Bethesda Guidelines for the Identification of MSH2/MLH1 Gene Carriers in Patients with Newly Diagnosed Colorectal Cancer: Proposal of a New and Simpler Set of Recommendations. <i>American Journal of Gastroenterology</i> , 2006, 101, 1104-1111.	0.4	36
20	Laparoscopic-assisted vs. open colectomy for colorectal cancer: influence on neoplastic cell mobilization,. <i>Journal of Gastrointestinal Surgery</i> , 2001, 5, 66-73.	1.7	35
21	Cyclooxygenase 2 Expression in Colorectal Cancer with DNA Mismatch Repair Deficiency. <i>Clinical Cancer Research</i> , 2006, 12, 1686-1692.	7.0	35
22	Title is missing!. <i>Annals of Surgery</i> , 2003, 237, 368-375.	4.2	29
23	Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives. <i>Gastroenterology</i> , 2017, 153, 106-112.e2.	1.3	28
24	High incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndrome. <i>Endoscopy</i> , 2019, 51, 142-151.	1.8	26
25	NTHL1 biallelic mutations seldom cause colorectal cancer, serrated polyposis or a multi-tumor phenotype, in absence of colorectal adenomas. <i>Scientific Reports</i> , 2019, 9, 9020.	3.3	23
26	Genomic rearrangements in and are rare mutational events in Spanish patients with hereditary nonpolyposis colorectal cancer. <i>Cancer Letters</i> , 2005, 225, 93-98.	7.2	17
27	Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 611-621.e9.	4.4	17
28	Evaluation of PARVG located on 22q13 as a candidate tumor suppressor gene for colorectal and breast cancer. <i>Cancer Genetics and Cytogenetics</i> , 2003, 144, 80-82.	1.0	15
29	New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population. <i>PLoS ONE</i> , 2020, 15, e0243158.	2.5	14
30	Reduction of faecal immunochemical test false-positive results using a signature based on faecal bacterial markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1410-1420.	3.7	12
31	Non-Lynch Familial and Early-Onset Colorectal Cancer Explained by Accumulation of Low-Risk Genetic Variants. <i>Cancers</i> , 2021, 13, 3857.	3.7	8
32	Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test. <i>World Journal of Gastroenterology</i> , 2020, 26, 70-85.	3.3	8
33	Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation. <i>Clinical Epigenetics</i> , 2019, 11, 171.	4.1	7
34	A case report of gastrointestinal histoplasmosis in a patient treated with infliximab. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 690-692.	0.8	4
35	Sa1253 VERRUCOUS GASTRITIS MIGHT BE A RISK FACTOR FOR EARLY GASTRIC NEOPLASIA IN THE WEST. <i>Gastrointestinal Endoscopy</i> , 2018, 87, AB183.	1.0	3
36	Utilidad de la colonografÃa por tomografÃa computarizada en la deteccÃ3n de pÃ3lipos colorrectales. <i>Medicina ClÃnica</i> , 2004, 123, 41-44.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Late-Occurring Liver Metastases in Colorectal Cancer. <i>Digestive Diseases and Sciences</i> , 2005, 50, 345-347.	2.3	2
38	Endoscopic surveillance in patients with multiple (10–100) colorectal polyps. <i>Endoscopy</i> , 2015, 48, 56-61.	1.8	1
39	Predictive Value of Carcinoembryonic Antigen in Symptomatic Patients without Colorectal Cancer: A Post-Hoc Analysis within the COLONPREDICT Cohort. <i>Diagnostics</i> , 2020, 10, 1036.	2.6	1
40	Potential Involvement of NSD1, KRT24 and ACACA in the Genetic Predisposition to Colorectal Cancer. <i>Cancers</i> , 2022, 14, 699.	3.7	0